The relationship of industry structure to open innovation: cooperative value creation in pharmaceutical consortia
The relationship of industry structure to open innovation: cooperative value creation in pharmaceutical consortia
复制标题
DOI：
10.1111/radm.12364
复制
发表时间：
2020-01-01
期刊：
影响因子：
6.3
通讯作者：
West, Joel
中科院分区：
文献类型：
--
作者：
Olk, Paul;West, Joel
开放式创新研究以价值创造和价值获取为重点，明确或隐含地研究了合作的竞争影响。然而，迄今为止，这样的研究还没有考虑到一个重磅炸弹的产业结构对开放式创新的影响。在这里，我们研究了一种特殊形式的多边合作，开放的R&D联盟，其中合作的结果被允许溢出到成员和非成员一样。我们是在制药行业的背景下这样做的，这是一个稳定但分散的行业，其定义是不断寻找受强大专用性保护的重磅炸弹。使用一个新的数据集，我们确定了141个这样的财团，涉及两个或更多的30个最大的制药公司。我们发现，企业在财务上支持这样的财团，部分原因是他们的价值创造活动有利于成员，而不会破坏现有产业结构的价值捕获或其他方面。我们讨论了这些研究结果的影响，在重磅炸弹行业的多边合作的研究，更普遍的开放式创新。
With its focus on value creation and value capture, open innovation research explicitly or implicitly examines the competitive impacts of collaboration. However, to date such research has not considered the effects of a blockbuster industry structure upon open innovation. Here, we examine a particular form of multilateral collaboration, the open R&D consortium, in which the results from collaboration are allowed to spill over to members and nonmembers alike. We do so in the context of the pharmaceutical industry, a stable but fragmented industry defined by the ongoing search for blockbuster hits protected by strong appropriability. Using a novel data set, we identify 141 such consortia that involve two or more of the 30 largest pharma firms. We show that firms financially support such consortia, in part, because their value creation activities benefit members without disrupting the value capture or other aspects of the incumbent industry structure. We discuss the implications of these findings for research on multilateral collaboration in blockbuster industries, and open innovation more generally.